PACAP Peptide Target Draws $46M as Vedana Enters Migraine Race
Executive Summary
Vedana Therapeutics emerged from stealth on June 17, 2026 with a $46 million Series A round to develop antibody-based therapies targeting PACAP (Pituitary Adenylate Cyclase-Activating Polypeptide), a neuropeptide that drives migraine through a pathway distinct from the well-established CGRP mechanism. The launch intensifies a competitive field that now includes Lundbeck (Phase II), Mentari Therapeutics (reverse-merger IPO), and Slate Medicines ($130M raised), turning PACAP into one of the most watched peptide targets in neurology.
Context / Background
For the past seven years, migraine prevention has been dominated by CGRP-targeting therapies — monoclonal antibodies like Aimovig (erenumab), Ajovy (fremanezumab), and Emgality (galcanezumab), plus oral gepants such as Nurtec and Qulipta. These drugs transformed a market previously reliant on repurposed antidepressants, beta-blockers, and Botox.
But the ceiling is clear: more than 50% of migraine patients either don’t respond to CGRP therapies or discontinue them due to inadequate relief or side effects. That leaves roughly 500 million people worldwide — half the estimated 1 billion migraine sufferers — without an effective targeted preventive. PACAP represents the most promising orthogonal mechanism to close that gap.
PACAP is a 38-amino acid neuropeptide in the VIP/secretin/glucagon superfamily. It binds to three receptors (PAC1, VPAC1, VPAC2) and is implicated in migraine pathogenesis through vasodilation, mast cell degranulation, and trigeminal nociception — overlapping with CGRP biology but sufficiently distinct that non-responders to one pathway may respond to the other.
The Data / The Deal / The Decision
| Metric | Value | Context |
|---|---|---|
| Vedana Series A | $46 million | Co-led by Westlake BioPartners & Canaan Partners |
| CGRP non-responder rate | >50% | Per multiple real-world studies; represents ~500M patients globally |
| Lundbeck PACAP program (ALD1910) | Phase II | Acquired via $2B Alder BioPharma deal (2019) |
| Slate Medicines funding | $130 million | RA Capital, Forbion, Foresite Capital |
| Mentari Therapeutics path | Reverse merger | Announced May 2026 |
| Vedana programs | 2 (mono + bispecific) | Anti-PACAP alone; anti-PACAP/CGRP dual-targeting |
| First human trials (Vedana) | Expected 2027 | Series A runway sufficient to reach clinic |
| Global migraine prevalence | ~1 billion | WHO Global Burden of Disease; #1 cause of disability in under-50s |
Expert Insight
Anti-pattern: Assuming PACAP is “just another CGRP.” Teams entering this space often treat PACAP as a straightforward follow-on target — and get burned by the biology. PACAP has broader physiological roles than CGRP, including regulation of circadian rhythm, stress response, and glucose homeostasis. The PAC1 receptor in particular has splice variants with opposing signaling biases. An antibody that blocks PACAP indiscriminately may show efficacy in migraine but produce unexpected metabolic or psychiatric side effects. Experienced teams are investing heavily in receptor-subtype selectivity and PK/PD modeling before the clinic — not after a Phase II safety signal.
Second pitfall: assuming the dual-targeting antibody is automatically superior. Vedana’s PACAP/CGRP bispecific is intellectually appealing — cover both pathways, capture more responders. But in practice, dual-targeting antibodies face manufacturing complexity, immunogenicity risk, and a higher bar for demonstrating added benefit over monotherapy in regulatory studies. The FDA will want to see that the bispecific is meaningfully better than an anti-PACAP antibody alone, not just non-inferior. That means larger, longer trials — and Vedana’s $46M won’t cover that. A partnership or follow-on round before Phase II is almost certain.
Frequently Asked Questions
What is PACAP and why is it a migraine target?
PACAP (Pituitary Adenylate Cyclase-Activating Polypeptide) is a 38-amino acid neuropeptide that triggers migraine-relevant processes including cranial vasodilation, mast cell degranulation, and activation of trigeminal nociceptive pathways. Unlike CGRP, PACAP also signals through the PAC1 receptor, which is highly expressed in the trigeminal autonomic system. Clinical evidence shows that PACAP infusion triggers migraine-like attacks in migraineurs but not in healthy controls, confirming its disease-specific role. Blocking PACAP or its receptors is expected to prevent migraine attacks in patients who don’t respond to CGRP therapies.
How is Vedana different from other PACAP developers?
Vedana’s key differentiator is its leadership team: CSO Leon Garcia oversaw discovery of Alder BioPharmaceuticals’ migraine programs (now Lundbeck’s); CMO Ernesto Aycardi managed pivotal and post-marketing studies for Teva’s Ajovy; board chair Rob Lenz led global development for Amgen’s Aimovig. This is the team that built the CGRP antibody market. Vedana is advancing two programs — a selective anti-PACAP antibody and a PACAP/CGRP bispecific — positioning it to cover both PACAP-only responders and those who might benefit from dual-pathway blockade. Human trials are expected in 2027.
What does this mean for the broader peptide therapeutics market?
The PACAP race validates a broader trend: neuropeptide targets are entering their second wave. After the commercial success of CGRP antibodies (combined market exceeding $10 billion annually), drug developers are systematically mining the neuropeptide family — PACAP, VIP, amylin, and orexin among them — for high-value neurological indications. The Vedana launch also signals that venture capital views peptide-targeting biologics as investable at the Series A stage, not just as Big Pharma licensing plays. Expect more neuropeptide startups in 2026–2027, particularly around targets with existing human validation (provocative infusion data, genetic linkage).
Further Reading
- GLP-1 Receptor Agonists: Beyond Diabetes and Weight Loss
- Peptide Drug Conjugates: Clinical Pipeline Review 2026
- Neuropeptide Therapeutics: The CGRP Playbook and What Comes Next
Last reviewed: June 2026. Peptide Proof Editorial Team. Source: BioPharma Dive, June 17, 2026 — “A new Westlake-backed biotech takes aim at migraines” by Jacob Bell.
